Abcam, ab227897, Human TLR2 ELISA Kit

Size: 1 x 96Tests
Human TLR2 ELISA Kit is a single-wash 90-min Simplestep used to quantify Human TLR2 with a sensitivity of 17 pg/ml. The assay uses a simple mix-wash-read protocol with just one incubation and one wash step. - Colorimetric Sandwich ELISA - 450 nm readout : works on any standard plate reader - Design your own immunoassay: we also offer the conjugation-ready antibody pair
Key facts
Detection method:Colorimetric,
Sample types:Urine, Heparin Plasma, Citrate plasma, Milk, Serum, Cell Lysate, EDTA Plasma,
Reacts with:Human,
Assay type:Sandwich (quantitative),
Sensitivity:= 17 pg/mL,
Range:109.4 - 7000 pg/mL,
Assay time:1h 30m,
Assay Platform:Pre-coated microplate (12 x 8 well strips)

Product details:
Human TLR2 ELISA Kit (ab227897) is a single-wash 90 min sandwich ELISA designed for the quantitative measurement of TLR2 protein in cit plasma, edta plasma, hep plasma, milk, serum, urine, and cell lysate. It uses our proprietary SimpleStep ELISA® technology. Quantitate Human TLR2 with 17 pg/ml sensitivity.
SimpleStep ELISA® technology employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our SimpleStep ELISA® plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time. See the SimpleStep ELISA® protocol summary in the image section for further details. Our SimpleStep ELISA® technology provides several benefits:
- Single-wash protocol reduces assay time to 90 minutes or less
- High sensitivity, specificity and reproducibility from superior antibodies
- Fully validated in biological samples
- 96-wells plate breakable into 12 x 8 wells strips
A 384-well SimpleStep ELISA® microplate (
ab203359
) is available to use as an alternative to the 96-well microplate provided with SimpleStep ELISA® kits.
The standard is affinity purified.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Toll-like receptor 2 (TLR2) also called CD282 is a protein that detects molecules from bacteria and fungi. It has a mass of about 90 kDa. TLR2 is expressed on the surface of immune cells such as monocytes macrophages and neutrophils. This receptor recognizes pathogen-associated molecular patterns (PAMPs) and activates the immune response.
Biological function summary
TLR2 initiates signaling pathways that lead to the production of cytokines and chemokines helping to control infection. It forms dimers with other TLRs like TLR1 or TLR6 to expand its recognition range of microbial components. TLR2's activity is important for balancing pathogen recognition and avoiding overactive immune response. On macrophages TLR2 activation enhances their phagocytic ability.
Pathways
TLR2 plays roles in innate immune signaling pathways and inflammation pathways. It contributes significantly to the NF-kB and MAPK pathways which regulate inflammation and immune response. TLR2 often cooperates with proteins like MyD88 and TRAF6 in these pathways leading to downstream activation of transcription factors and production of pro-inflammatory molecules.
TLR2 is associated with inflammatory and infectious diseases including sepsis and tuberculosis. During tuberculosis interactions between TLR2 and its ligands trigger immune responses that are important for bacterial control. Additionally TLR2’s overactivation links to sepsis by causing excessive inflammation. Researchers study TLR2 for potential therapeutic targeting in these diseases assessing how modulation can improve outcomes or reduce detrimental inflammation.